Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
In 1965 the first study of this series reported different effects of neuroleptics in rats, supporting clinical differences. At the one end, haloperidol presented as a potent and specific antagonist of the psychostimulants amphetamine and apomorphine. Haloperidol-like neuroleptics have marked effects on psychomotor agitation, delusions and hallucinations and bind with high affinity to dopamine-D2 receptors. Pipamperone, at the other end, presented with weak "dopamine" antagonism and more striking tryptamine antagonism. Pipamperone is known to improve disturbed sleep, social withdrawal and other symptoms of chronic schizophrenia in the relative absence of extrapyramidal symptoms. These effects have been attributed to central serotonin-S2 antagonism, on the basis of the clinical effects of ritanserin. As shown by the present analysis of relative tryptamine versus apomorphine antagonism of 57 neuroleptics, in comparison to relative S2 vs. D2 binding, there is a continuity in the series. About 30% of the compounds can be considered to act primarily as serotonin antagonists, but few are markedly more potent than pipamperone. In amphetamine-challenged rats pipamperone-like activity is reflected in preferential inhibition of the excessive oxygen consumption rather than of agitation. Risperidone inhibits oxygen consumption (0.016 mg/kg) at the same dose as haloperidol inhibits agitation. Other low-dose effects of risperidone include reversal of amphetamine-induced withdrawal, antagonism of agitation induced by a sequential tryptamine and apomorphine challenge and LSD-antagonism. In dogs, the antiemetic activity of risperidone is characterized by high oral effectiveness which lasts one day and agrees with pharmacokinetic data when allowance is made for the active metabolite 9-hydroxyrisperidone.(ABSTRACT TRUNCATED AT 250 WORDS)
Janssen
P A
PA
Janssen Research Council, Beerse, Belgium.
Awouters
F H
FH
D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001058:Apomorphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002090:Butyrophenones / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D065127:Dopamine D2 Receptor Antagonists; D006220:Haloperidol / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D007555:Isoxazoles / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D008238:Lysergic Acid Diethylamide / Q000037:antagonists & inhibitors; D009043:Motor Activity / Q000187:drug effects; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D010880:Piperidines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy; D012702:Serotonin Antagonists; D013045:Species Specificity; D014363:Tryptamines / Q000037:antagonists & inhibitors / Q000494:pharmacology
D014150:Antipsychotic Agents; D002090:Butyrophenones; D065127:Dopamine D2 Receptor Antagonists; D007555:Isoxazoles; D010880:Piperidines; D012702:Serotonin Antagonists; D014363:Tryptamines; C005569:pipamperone; D008238:Lysergic Acid Diethylamide; D000661:Amphetamine; D006220:Haloperidol; D018967:Risperidone; D001058:Apomorphine